Omalizumab and the World Health Organization. It is also used to treat people 12 years and above with chronic spontaneous urticaria (also called chronic idiopathic urticaria), which cannot be treated with elevated doses of H1-antihistamines. The main adverse effect is anaphylaxis (a life-threatening systemic allergic reaction), with a rate of occurrence of 1 to 2 patients per 1,000. Like other protein and antibody drugs, omalizumab also causes anaphylaxis, although at a relatively low frequency among antibody drugs. The allergic reaction is probably not due to the binding characteristics of the antibody drug, but to the protein nature of the antibody. The
Allergic response produce histamines. These histamines will act on different areas of the body (eyes, throat, nose, gastrointestinal tract, skin or lungs) to produce symptoms of an allergic reaction. The allergic response is not limited to a certain amount of exposure. If the body is exposed to the allergen multiple times the immune system will react every time the allergen is present. The reason why people get allergies is not known. The allergens are not passed down through generations. It is believed if parents have allergies the child is more likely to be allergic to the same allergens. Some common symptoms include